Evidence map›Paper›PMID 25685660›Full record

ArticleFEBS open bio2015

Secretory prostate apoptosis response (Par)-4 sensitizes multicellular spheroids (MCS) of glioblastoma multiforme cells to tamoxifen-induced cell death.

Jayashree C Jagtap, D Parveen, Reecha D Shah, Aarti Desai, Dipali Bhosale, Ashish Chugh, Deepak Ranade, Swapnil Karnik, Bhushan Khedkar, Aaishwarya Mathur and 3 more

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Biomaterial-basedCancer pathogenesis and therapy · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Jayashree C JagtapNational Centre for Cell Science (NCCS), Pune, India.
D ParveenNational Centre for Cell Science (NCCS), Pune, India.
Reecha D ShahNational Centre for Cell Science (NCCS), Pune, India.
Aarti DesaiPersistent Systems Ltd., Pune, India.
Dipali BhosalePersistent Systems Ltd., Pune, India.
Ashish ChughDepartment of Neurosurgery, Cimet's Inamdar Multispeciality Hospital, Pune, India.
Deepak RanadeDepartment of Neurosurgery, D.Y. Patil Medical College, Pune, India.
Swapnil KarnikDepartment of Histopathology, Ruby Hall Clinic, Pune, India.
Bhushan KhedkarDepartment of Histopathology, Ruby Hall Clinic, Pune, India.
Aaishwarya MathurNational Centre for Cell Science (NCCS), Pune, India.
Kumar NateshNational Centre for Cell Science (NCCS), Pune, India.
Goparaju ChandrikaNational Centre for Cell Science (NCCS), Pune, India.
Padma ShastryNational Centre for Cell Science (NCCS), Pune, India.
National Centre for Cell Science · INPersistent Systems (India) · INRuby Hall Clinic · INDr. D. Y. Patil Medical College, Hospital and Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most malignant form of brain tumor and is associated with resistance to conventional therapy and poor patient survival. Prostate apoptosis response (Par)-4, a tumor suppressor, is expressed as both an intracellular and secretory/extracellular protein. Though secretory Par-4 induces apoptosis in cancer cells, its potential in drug-resistant tumors remains to be fully explored. Multicellular spheroids (MCS) of cancer cells often acquire multi-drug resistance and serve as ideal experimental models. We investigated the role of Par-4 in Tamoxifen (TAM)-induced cell death in MCS of human cell lines and primary cultures of GBM tumors. TCGA and REMBRANT data analysis revealed that low levels of Par-4 correlated with low survival period (21.85 ± 19.30 days) in GBM but not in astrocytomas (59.13 ± 47.26 days) and oligodendrogliomas (58.04 ± 59.80 days) suggesting low PAWR expression as a predictive risk factor in GBM. Consistently, MCS of human cell lines and primary cultures displayed low Par-4 expression, high level of chemo-resistance genes and were resistant to TAM-induced cytotoxicity. In monolayer cells, TAM-induced cytotoxicity was associated with enhanced expression of Par-4 and was alleviated by silencing of Par-4 using specific siRNA. TAM effectively induced secretory Par-4 in conditioned medium (CM) of cells cultured as monolayer but not in MCS. Moreover, MCS were rendered sensitive to TAM-induced cell death by exposure to conditioned medium (CM)-containing Par-4 (derived from TAM-treated monolayer cells). Also TAM reduced the expression of Akt and PKCζ in GBM cells cultured as monolayer but not in MCS. Importantly, combination of TAM with inhibitors to PI3K inhibitor (LY294002) or PKCζ resulted in secretion of Par-4 and cell death in MCS. Since membrane GRP78 is overexpressed in most cancer cells but not normal cells, and secretory Par-4 induces apoptosis by binding to membrane GRP78, secretory Par-4 is an attractive candidate for potentially overcoming therapy-resistance not only in malignant glioma but in broad spectrum of cancers.

Indexed as

CM, conditioned mediumCytotoxicityDrug resistanceGBM, glioblastoma multiformeGlioblastomaLGG, low grade gliomasMCS, multicellular spheroidsMulticellular spheroids (MCS)Par-4TamoxifenTAM, tamoxifenTCGA, The Cancer Genome Atlas

Identifiers

PMID25685660
PMCPMC4309838
OpenAlexW2020968654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.